News

Back

TheraVet strengthens its sales organisation in France by signing an important distribution agreement for BIOCERA-VET®

January 18th 2022

BSCB Dev

TheraVet, a biotech company developing pioneering treatments for osteoarticular disease in pets, announced today the signature of a non-exclusive commercial distribution agreement for its BIOCERA-VET® bone substitute in France with the veterinary co-operative Centravet, one of France’s leading wholesaler/distributors of animal health products. The agreement covers the BIOCERA-VET®-Bone Surgery (BS) and BIOCERA-VET®- Osteosarcoma (OSA) product lines.

Read Pdf